Chiltern Welcomes Gastroenterology, Oncology and Pediatric Therapeutic Experts to Their Team

LONDON, Jan. 31, 2012 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that Drs. Marcelo Piccirillo and Carlo Lanza have joined Chiltern, bringing their expertise in the areas of gastroenterology, oncology and pediatrics to serve our clients' needs.

"We are delighted to announce the addition of Drs. Marcelo Piccirillo and Carlo Lanza to Chiltern's Medical team. They strengthen our capabilities in the prominent clinical study areas of gastroenterology, oncology and pediatrics," commented Sharon Moore, MD, Executive VP, Global Quality & Medical Affairs, Chiltern. "These are key therapeutic positions and Drs. Piccirillo and Lanza bring a wealth of experience which enhances our operational delivery and consultative approach for our clients."

Marcelo Piccirillo, MD, will serve as Sr. Clinical Research Physician based out of the Wilmington, USA office with special emphasis in developing the gastroenterology therapeutic area. Dr. Piccirillo has 20 years experience in the medical and clinical research industry including 7 years as a general and colorectal surgeon. His extensive clinical research therapeutic experience includes a variety of indications such as gastroenterology, pulmonary (asthma/COPD), oncology, neurology, diabetes, metabolic disease, drug safety and medical monitoring of clinical trials among others. In the past five years Dr. Piccirillo has worked extensively in the areas of Inflammatory Bowel Disease (IBD) and colonic transit disorders.

Carlo Lanza, MD, will serve as Sr. Clinical Research Physician based out of the Milan, Italy office to support and expand Chiltern's global activities in the oncology, hematology and pediatric therapeutic areas. Dr. Lanza has over 20 years of clinical research experience, including more than 10 years in academic medicine and clinical practice. During the last several years Dr. Lanza has served in extensive medical lead roles at large pharma companies and international organizations in the therapeutic areas of oncology, hematology, pediatrics and malaria R & D at a global level, including major clinical leadership activities in emerging markets in Asia and Africa.

Dr. Piccirillo is board-certified in General Surgery from the Hospital Evita, Buenos Aires, Argentina and completed a colorectal surgery fellowship at Cleveland Clinic Florida, USA with a special focus on IBD, colorectal cancer and other colonic transit disorders.

Dr. Lanza received MD and PhD degrees from the University of Turin, Italy with Italian board certification in pediatrics and completed an MSc in Hematology at the University of London. He is a member of the Italian Medical Order, the General Medical Council (GMC) UK and American Society of Hematology (ASH).

Both physicians are widely-published.

Company profile

About Chiltern:

Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs nearly 1,300 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. Further information is available at: www.chiltern.com.

SOURCE Chiltern